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ReimbursementAbstract In recent decades cancer care has seen improvements in the speed and accuracy of
diagnostic procedures; the effectiveness of surgery, radiation therapy and medical treatments;
the power of information technology; and the development of multidisciplinary, specialist-led
approaches to care. Such innovations are essential if we are to continue improving the lives of
cancer patients across Europe despite financial pressures on our healthcare systems. Invest-
ment in innovation must be balanced with the need to ensure the sustainability of healthcare
budgets, and all health professionals have a responsibility to help achieve this balance. It re-
quires scrutiny of the way care is delivered; we must be ready to discontinue practices or in-
terventions that are inefficient, and prioritise innovations that may deliver the best outcomes
possible for patients within the limits of available resources. Decisions on innovations should
take into account their long-term impact on patient outcomes and costs, not just their imme-
diate costs. Adopting a culture of innovation requires a multidisciplinary team approach, with
the patient at the centre and an integral part of the team. It must take a whole-system and
whole-patient perspective on cancer care and be guided by high-quality real-world data,
including outcomes relevant to the patient and actual costs of care; this accurately reflects
the impact of any innovation in clinical practice. The European CanCer Organisation is
committed to working with its member societies, patient organisations and the cancer commu-
nity at large to find sustainable ways to identify and integrate the most meaningful innovations
into all aspects of cancer care.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the last two to three decades, the field of cancer has
seen improvements in the speed and accuracy of diag-
nostic procedures [1], the effectiveness of surgery [2e4],
radiation therapy [5,6] and medical treatments [7,8] and
the power of information technology [9]. Development
of clinical support rolesdsuch as those of specialist
oncology nurses and of multidisciplinary, specialist-led
approaches to caredhave also played an important
role in improving the care offered to cancer patients.
Investment in all these innovations is critical if we are
to continue to improve the lives of cancer patients across
all age groups in years to come. However, there is
growing evidence of inequalities in, and complex barriers
to access to, many innovations in Europe, as healthcare
systems are increasingly challenging their costs, and out-
of-pocket payments for cancer care are growing [10,11].
Although much of the literature and policy debate
focuses on inequalities in access to anticancer medicines
[12,13], significant inequalities also exist for other as-
pects of cancer care. Within this context, it is critical to
balance investment in innovation with the need to
ensure the sustainability of healthcare budgets, and this
is a global concern [14e16].
In all countries, notions of innovation and value are
intrinsically linked. We need to apply more scrutiny to
the way we deliver care today, be ready to remove or
discontinue practices or interventions that are inefficient,
and be forward-thinking to prioritise innovations that
may deliver the best outcomes possible for patients with
the resources at hand. Implementation of innovations
also needs to follow a structured pathway, and practicesshould be adapted to accommodate them. Greater
transparency is needed on prices and pricing policies, as
has been called for by the European Cancer Leagues
Task Force for Equal Access to Cancer Medicines. This
being said, investment decisions on innovations should
consider the long-term impact of innovations on patient
outcomes and costs, not just their immediate costs.
All health professionals have a key responsibility to
help achieve this balance. Within this context, this
article offers a multidisciplinary perspective on how we
can responsibly and sustainably encourage access to the
most meaningful innovations for cancer patients in years
to come whilst improving on existing practice and
decreasing waste and inefficiencies across all aspects of
cancer care. It was developed by the European CanCer
Organisation (ECCO) with input from its member so-
cieties and the ECCO Patient Advisory Committee and
is intended as the basis for future actions to be taken by
relevant health professionals. These actions will be
developed into an action plan in the next few months.
2. How do we define innovation in cancer care?
It may be argued that the term ‘innovation’ has been
over-used in recent years and is usually thought of
simply as ‘something new’ [18,19]. However, ‘newer’ is
not necessarily better than older alternatives, and in
reality what constitutes an innovation is more nuanced.
Innovation can take place within any aspect of cancer
care. It does not have to be complex, or expensive;
simple interventions may often have the greatest impact
on improving patient care. In addition, meaningful
progress often occurs over time, as a result of a series of
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not necessarily be transformative in their own right.
It is also critical to recognise that innovation is an
evolving concept and must keep pace with our growing
understanding of cancer and treatment expectations.
For example, drug development models need to consider
expected patterns of relapse and disease evolution to
make sure that we are providing patients with the most
appropriate course of treatment and not simply making
decisions, one treatment at a time.
A definition of innovation that transcends these
complexities is that it is any intervention within the care
pathway that makes a meaningful difference to patients.
With this definition in mind, member organisations of
ECCO have made suggestions as to what aspects of
cancer care represent the most meaningful innovations
in their view and which practices should be considered
as obsolete as they do not offer benefits to patients (see
Table 1). These suggestions will be discussed and pri-
oritised as a next step in this initiative by ECCO and its
member organisations.
3. How does one measure the value of innovation?
Defining the value of an innovation requires a compre-
hensive assessment of its impact on patient outcomes,
quality of life, quality of care and costs across the
system.
The necessary starting point to the measurement of
value of any innovation is to determine whether it offers
real benefits to patients. Over the past few years, the
European Society for Medical Oncology (ESMO),
American Society of Clinical Oncology, European So-
ciety for Radiotherapy and Oncology (ESTRO) and
other professional societies have called for a more
consistent approach in the evaluation of new treatments
and have proposed new measures aimed at capturing the
real benefit of anticancer medicines and other technol-
ogies [20e22]. For example, ESMO’s Magnitude of
Clinical Benefit Scale (ESMO-MCBS) aims to ‘help
frame the appropriate use of limited public and personal
resources to deliver cost-effective and affordable cancer
care’ [20]. The ESMO-MCBS is an important innovative
instrument but is based solely on data from clinical
trials, without consideration of costs [23]. Other scales
include costs [24], however in Europe these vary from
country to country. The ESMO-MCBS was initially
developed without input from patients [25].
These limitations point to the need to consider the
value of new interventions from the patient’s perspec-
tive, giving adequate weight to quality of life and
progression-free survival, and not only overall survival,
and with input from all stakeholders.
Real-world data (from registries, large databases and
big data initiatives) are part of the continuum of clinical
research. They are key to determining whether benefits
observed in clinical trials are also seen in unselectedpatientpopulations in real-world settings and to understanding
the impact of a given innovation on patient outcomes.
Real-world data should also include the full costs of care.
Real-world data are very important for surgical tech-
niques and medical devices, for which typically the data is
much scarcer at the time of regulatory approval than for
medicines. The IDEAL collaboration (Idea, Develop-
ment, Exploration, Assessment, Long-term Follow-up,
Improving the Quality of Research in Surgery) has rec-
ommended that real-world data on the efficacy and safety
of any new surgical procedure [26] or medical device
[27,28] should be collected as soon as it is introduced into
clinical practice, to guide clinical guidelines and improve
the use of these procedures in clinical practice.
Real-world data are particularly critical in the case of
rare adult cancers and paediatric cancers, as small patient
numbers may limit the potential to gather sufficient evi-
dence within traditional clinical trial settings. They are
also a key component of ‘coverage with evidence’ schemes
increasingly being used for new anticancer medicines,
particularly ‘breakthrough innovations’ that are approved
on the basis of early-stage trial data through accelerated
approval schemes. These medicines may be granted pro-
visional reimbursement based on early clinical trial data,
on the condition that this decision is to be reviewed, and
access potentially expanded, at a later timepoint once real-
world data on the impact of this intervention are available.4. What are barriers to the development and uptake of
innovation?
Barriers may occur at different stages: research and
clinical trials / regulatory approval (European Medi-
cines Agency [EMA] and national) / national and
regional access decisions (health technology assessment
[HTA] or pricing and reimbursement) / uptake into
local practice.4.1. Research and clinical trials
There are numerous barriers to the development of
innovative medicines, diagnostics and technologies
during the research stage (e.g. in clinical trials), which
contribute to delaying individual patients’ access to in-
novations in areas of high unmet needs. These barriers
delay the generation of meaningful data and knowledge
from clinical research as well as the publication of
research findings, leading to delays in the time it takes
for an innovation to be adopted post-approval into
clinical practice. Barriers in research often result from
the absence of collaboration across disciplines and be-
tween different layers of healthcare provisioning (e.g.
primary care, community oncology care, hospitals and
academic centres), as well as insufficient information
provided to patients and healthcare professionals about
ongoing and completed research. Further barriers exist
Table 1
Defining areas of innovation and obsolescence across the cancer care spectrum.
Aspect of care Areas of innovation Examples of obsolescence
Psycho-oncology
[30]
Routine psychosocial distress screening using validated self-
report measures to identify cancer patients who should be
referred to psychosocial services
Reliance solely on clinician observations or patient requests
to identify cancer patients who should be referred to
psychosocial services
Oncology nursing
[46,47]
Increasing trained oncology nursing services in all European
countries
Lack of appropriate and specific funding for trained
oncology nurses
Supportive care and
rehabilitation
Providing adequate and appropriate supportive treatments
over the entire course of care
Assessing the impact of treatment side-effects (physical,
emotional, cognitive, sexual and nutritional) and develop a
rehabilitation/survivorship plan to address and reduce those
symptoms and problems
Insufficient supportive care leading to worse patient
outcomes
Genetics [7] Improved understanding of predisposition factors and use
of these data to better characterise a tumour’s aetiology and
adapt therapy where supported by evidence
Pathology [1,7,48] Identification of molecular markers of prognostic or
predictive value using various methodologies
Quality control of pathology
Research-based ‘liquid biopsies’ for characterising and
monitoring tumours
Decision-making without use of such tools, when
adequately recognised by scientific evidence
Monitoring [49] Use of advanced imaging techniques to define disease extent
and tailor treatment
Unjustified staging examinations
Unjustified follow-up procedures
Adjuvant treatment
[5,50]
Defining the need for long-term treatment versus shorter
treatments
Development of adjuvant treatments in specific biologically
defined patient subsets
Further exploration of how neo-adjuvant treatment results
could be appropriately used to select adjuvant treatment
and therefore avoid ‘blind’ adjuvant treatments
Studies that are not based on the present understanding of
the biology of various tumour subtypes
Surgery [51e53] Optimisation and standardisation of cancer surgery with
educational programmes and quality assessment e.g.
introduction of total mesorectal excision (TME) in
colorectal cancer surgery
Technological advances: e.g. minimally invasive surgery and
interventional radiology to reduce short- and long-term
negative outcomes
When a new procedure is of proven benefit, make it
accessible and develop centre expertise to ensure its
appropriate use
Surgery performed in multiple low-volume centres with
inadequate demonstration of expertise and quality results
Radiation therapy Development of radiation therapy facilities according to
standards supported by ESTRO, with image-guided
radiation therapy, modulated and adaptive techniques and
specific particle therapy facilities
When a new procedure is of proven benefit, make it
accessible and develop centre expertise to ensure its
appropriate use
Radiation therapy performed in multiple low-volume
centres with inadequate demonstration of expertise and
quality results
Medicines [20] Development of the use of the ESMO evaluation system
(ESMO relative value scale) to prioritise medicines of
greatest benefit to patients
Use of local scoring systems to decide whether or not to
include a given medicine in a formulary
Geriatric oncology
[54]
Screening for frailty and using geriatric assessment to
stratify older populations with cancer and adjust treatment
accordingly
Using civil or chronological age as a threshold for making
strategic decisions related to a patient’s care
Paediatric oncology
[55,56]
(also valid in
adult treatment)
Accelerated and early access to innovative therapies during
their development
Novel immunotherapeutic approaches and medicines
targeting epigenetics
Novel functional and statistical tools to assess objective
response and long-term survival benefit
Standardised assessment of toxicity with emphasis where
possible on patient-reported outcomes
Transparent and obligatory patient-oriented long-term
outcomes assessment
Repeating old and toxic therapies without any attempt to
improve practice based on knowledge of molecular
pathways and their function in different cancers
Use of new therapies based on ‘single-case evidence’, as
opposed to multicentre clinical trialsdas was the case with
haematopoietic stem cell transplantation years ago
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Table 1 (continued )
Aspect of care Areas of innovation Examples of obsolescence
Big data [57,58] Facilitate the exchange of ‘big data’ among different
European countries in order to ameliorate, among other
things, the quality of overall therapy
Perpetuation of siloed, disjointed health information
systems and lack of cohesive solutions across different
settings of care
Registries [59e62] Making cancer registries an obligatory part of Europe-wide
registration of any cancer type
Use of epidemiological data to evaluate different practices
and outcomesdto drive future treatment plans towards the
most effective practices
Lack of such an approachdresulting in perpetuation of
ineffective practices that could have been identified through
appropriate data and research
Care planning
[63,64]
Shaping future services in response to national cancer
experience surveys of people living with cancer
Lack of multidisciplinary decision-making and out-of-date
uni-disciplinary attitudes
Lack of role development opportunities for the cancer
workforce. These are necessary to respond to rising demand
and patient expectations
Professional
education [45]
Knowledge transfer across all relevant disciplines to apply
novel techniques in diagnostics and treatment
Professional education programmes to extend knowledge to
all relevant specialities of:
 the principles of risk assessment for acute
complications
 the principles of risk assessment for long-term
outcomes and sequelae of treatment
Development of a Europe-wide qualification and
certification system in oncologyde.g. in the form of cross-
border educational programmesdwith transparent
standards for quality assessment
Extending knowledge to all health professionals involved in
cancer care that health education, physical activity and
lifestyle should be implemented to improve cancer care and
quality of life for patients
Clinical research
[43,44]
New models of clinical studies developed in cooperation
with population-based registries
New types of access platforms where single cohort patients
can be benchmarked to contemporary real-life patients
New partnerships between academia/government and
industry to allow
 more ‘risky’ treatment arms in the design of registra-
tion trials (such as short exposure to a new drug)
 sharing of anonymised individual patient biomarker
and efficacy data from registration trials according to
a predefined timing, thereby allowing data protection
for only a limited period
Regulatory [65] Solutions for efficiently bringing the most promising
therapeutic solutions to patients (e.g. adaptive licencing and
accelerated approval schemes)
Better coordination of European Commission directorates
(DG Sante´, DG Research and so forth) to enable optimal
access of patients to trials and treatments
Perpetuation of distinct mechanisms and policies within the
European Commission leading to disjointed practices
between the different directorates
Lack of harmonisation of regulatory practices across
Europe, despite EMA centralised procedures, as well as
different evidentiary requirements between countries leading
to slow uptake of innovations
ESTROZEuropeanSociety forRadiotherapyandOncology;ESMOZEuropeanSociety forMedicalOncology;EMAZEuropeanMedicinesAgency.
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There is also a lack of large pan-European studies rather
than regional or local studies with insufficient power to
answer relevant clinical questions.4.2. Regulatory approval
Processes to obtain regulatory approval for surgical pro-
cedures, radiation oncology and imaging techniques, andtheir introduction into centres, vary considerably across
Europe. As mentioned previously, the evidentiary re-
quirements for these procedures are typically much lower
than for medicines, often leaving it up to individual cli-
nicians to evaluate them over time. The IDEAL frame-
work mentioned previously calls for a much more
transparent, evidence-based system whereby real-world
evidence of the impact of new procedures is collected
prospectively, with the aim of creating an up-to-date
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and uptake of these technologies over time [26e28].
In the field of medicines, significant strides have been
made by regulatory agencies such as the EMA in recent
years to accelerate the approval of potential in-
novations. For example, special allowances for orphan
drugs and piloting of adaptive pathways by the EMA all
allow for greater flexibility in regulatory requirements
and more rapid access to new medicines by patients. The
new EU Clinical Trial Regulation [29]dwhich aims to
reduce some of the bureaucracy in clinical development
programmes by requiring only one application via a
single portal for trials conducted in several member
statesdmay also be an important development. For
paediatric cancers, the EU Paediatric Regulation has
significantly changed the landscape for new drug
development; however, significant unmet needs remain.
4.3. Reimbursement
Reimbursement or funding decisions for different com-
ponents of cancer care are often divided among different
decision bodies, who may base decisions on very
different types of evidence. Different components of
care are also evaluated and reimbursed separately. For
example, targeted therapies, multi-target combinations
thereof, as well as their companion diagnostics or bio-
markers are often not evaluated jointly, and medicines
given in hospital may be evaluated differently from
those given in an outpatient setting. Finally, as has been
mentioned previously, the level of evidence available to
judge the value of medicines, diagnostics, imaging and
surgical techniques may differ considerably, with phy-
sicians often asked to confirm the cost-effectiveness of
medical diagnostics, for example, without necessarily
having adequate training to do so.
A key issue is also that many reimbursement decisions
focus solely on the immediate budget impact of a given
intervention, so that even promising innovations are only
looked at in terms of their immediate costs, with little
consideration for their overall impact on healthcare uti-
lisation in terms of reduced hospitalisations or long-term
care, not to mention social costs such as fewer sick days
due to a better tolerability profile or fewer complications.
This is evident in the case of psychosocial support for
patients, which is not reimbursed in many European
countries. Even in countries where it is reimbursed, pa-
tients may not be reimbursed if they need to access psy-
chosocial care outside of their local area or from private
providers if these services are not available locally [30].
Another important limitation is that patients and
their representatives are too seldom involved in HTA
and other reimbursement decisions [31]. The inclusion of
patient experience data captured during clinical trials
would represent an important step forward from what is
currently provided for HTA and other reimbursement
submissions. This would contribute to providing a moreaccurate and relevant account of the impact of new
technologies on patients.
Finally, delays in reimbursement between countries
are an ongoing concern, as they cause inequalities in ac-
cess to care for patients across Europe. Looking specif-
ically atmedicines: in 1989, the EuropeanCommission set
a maximum limit of 180 days [32] between the time a
reimbursement dossier is submitted to the relevant na-
tional agency and market access is granted. Yet many
countries continue to exceed this time limit, particularly
in Central Eastern European countries (2008e2010 data)
[33] and the United Kingdom. Reimbursement sub-
missions are done on a countrydand sometimes even a
regionaldlevel, with significant differences in access be-
tween andwithin countries as a result [9]. The recent work
of the European Network for Health Technology
Assessment (EUNetHTA) has helped in trying to increase
collaboration between agencies and harmonise the evi-
dence requirements across different HTA agencies,
hopefully contributing to closer alignment when new
medicines become available to patients in different
countries. Needless to say, similar alignment is also
needed for other aspects of cancer care.
4.4. Local uptake
There are known variations in the uptake of innovations
across different care settings, often reflecting variations
in the quality of care offered between specialised and
non-specialised centres. Lack of specialisation may also
increase the reliance on outdated or ineffective treat-
ment approaches that could be replaced by more effec-
tive ones, thereby compromising the integration of
innovative approaches into patient care.
A chosen approach in several countries has been to
create designated ‘centres of excellence’ (or specialised
centres). This centralisation may help to ensure con-
sistency of quality across designated centres and allow
for economies of scale in the purchase of imaging and
other expensive equipment. Delivery of cancer care in
specialist centres is particularly critical for rare cancers,
as the small number of cases means that it is difficult
for physicians to acquire sufficient experience and
expertise in their treatment and care. To this end, Rare
Cancers Europe has recommended that care for rare
cancers be centralised in European Reference Net-
works (ERNs), of which three cover rare cancers
(ERNs on rare adult solid tumours, blood disease and
paediatric cancers).
With the development of ERNs and other centres of
excellence, however, it will be important to make sure
that centralisation of care does not create additional
barriers to care for patients and that they work in close
networks with local practitioners as part of a multidis-
ciplinary care team adhering to the same protocols and
guidelines. This networked model of care is already
being implemented for children and adolescents with
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Oncology has defined the European Standards of Care
for Children with Cancer [34].
A critical issue for centres of excellence is that they
meet clear standards or essential requirements. For
example, many hospitals that have so-called specialist
cancer services are not organised into multidisciplinary
units, as recommended by ECCO and other professional
societies [35e37]. To this end, ECCO is currently
developing essential standards to ensure a more consis-
tent level of quality within designated specialised cen-
tres, looking specifically at colorectal cancer and bone
and soft-tissue sarcomas [38,39].
An interesting example of the application of essen-
tial requirements is the designation of specialist breast
units. Essential requirements were outlined by the
European Society of Mastology in 2000 and updated in
2013 [40,41] and include a minimum caseload (>150
newly diagnosed cases per year), an audited database
of quality indicators and research, multidisciplinary
case management meetings, clear verbal and written
patient information, and defined teaching and research
plans [42].
Implementation of innovations may also be facili-
tated by the expansion of ‘coverage with evidence
development’ (CED) schemes, which should be applied
to all types of innovations, not just medicines. These
schemes should be guided by health economic simula-
tions in the early stages of research, and the availability
of health economic expertise and knowledge to help
guide implementation of CED schemes and data
collection within each institution. Close collaboration
with professional societies is also needed to ensure
acceptance of innovations within practice guidelines.5. Improving access to innovation in cancer care: potential
solutions
Improving accessdand overcoming some of the existing
hurdles to accessdto innovation will require a combi-
nation of levers at the political, system and individual
hospital or clinic level. These are described in the
following section.
5.1. Greater involvement of patients and caregivers in
defining and assessing the value of innovation
 Comprehensive assessment of the impact of innovations on
patients’ quality of life, risk/benefit balance and overall
experience of care must be an integral part of the evaluation
of any innovation, by using validated patient-reported
outcomes and experience measures.
 Patients and their representatives should be involved early
in the planning and conduct of research, as well as regu-
latory and HTA discussions related to innovation, to ensure
that their perspectives guide the development and evalua-
tion of innovations. Patient organisations should be supported to develop
accessible information materials to inform the patient
community about upcoming innovations with close
collaboration from clinical specialists. They may act as
powerful advocates for the integration of innovations into
clinical practice and acceptability in the broad patient
population.
5.2. A whole-system, whole-patient approach to guide
investment in innovation
 Despite the continual focus on cost containment in
healthcare, national governments should foster an innova-
tion agenda by adopting a system-wide strategy for in-
vestment in innovation.
 This strategy should
 be guided by identified patient needs, as measured by
patient-relevant outcomes, with more research needed in
close partnership with patient organisations to better
understand unmet patient needs (clinical but also psy-
chosocial and emotional), relevance and priorities in
different cancers and where the need for innovation is
greatest;
 take a ‘whole-system’ as well as a ‘whole-patient’
approach, looking at what innovations may have the
most impact across the entire care pathway, and moving
away from siloed decisions on different types of care (e.g.
medicines, medical devices, equipment, radiology and
surgery).
5.3. More efficient and harmonised evaluation of
innovation
 The evaluation of all innovations should be centralised and
harmonised at a national or regional level, with a credible
multidisciplinary group of stakeholders guiding decisions.
This should ideally free individual hospitals or departments
from having to make decisions about the value of in-
novations and create a more transparent evidence base on
which investment in innovations may be made across
different settings of care.
 Greater transparency in the evidence required for HTA and
reimbursement decisions for all types of diagnostic pro-
cedures and care is also needed, including
 closer alignment between these decisions and regulatory
bodies to avoid unnecessary delays in access to patients;
 where possible, greater alignment between countries in
terms of HTA and reimbursement decisions, making
greater use of EUNetHTA or similar entities for a coor-
dinated approach between HTA agencies.
5.4. Investment in real-world data to guide investment in
innovation
 Investment in well-designed registries, big data and other
real-world data collection is key to assess the potential
impact of innovations in clinical practice. Harmonisation of
data sets both within and between countries is needed for us
to be able to pool data from different sources. Real-world
data may be used to guide:
 reimbursement decisions, looking at the impact on costs
and outcomes across the entire care pathway, and thereby
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alone. Ideally, this process should be reviewed regularly,
based on new data emerging over time;
 investment and integration of innovations into clinical
practice;
 updating of clinical guidelines to reflect why a given
intervention has not been integrated into the guideline
based on evolving data on its effectiveness.
 Efforts to improve the potential for sharing of registry data
across different countries are also needed; an example is the
EMA project which is looking at making better use of
existing patient registries and supporting the set-up of new
ones on the basis of common protocols, scientific methods,
structures, data sharing and transparency [43,44].
5.5. Promotion of an innovation culture within the delivery
of cancer care
 The implementation of multidisciplinary teams (MDTs)
across cancer care may compel individual specialists to look
beyond their own area of expertise and take a whole-system
approach to innovation, focussing on innovations that may
make the greatest difference to patients, and adapt care
pathways to integrate them into practice, and, together,
ask: ‘How can we do things better?’ [35]
 MDTs may also provide an opportunity to continuously
review clinical practice and stop wasting resources on things
that have become inferior compared to updated standards
and could be replaced by more efficient, innovative prac-
tices [35].
 New models of cancer care integrating primary care and
secondary care need to be established to improve the
quality of care, starting with an effective diagnosis.
 Continued educational efforts are also needed to dissemi-
nate existing guidelines to physicians and encourage their
implementation, with specialist centres taking the lead in
educational activities, on-site training, webinars or other
information-sharing activities to keep everyone up-to-date
on advances in care. European reference documents such as
the European Guide on Quality National Cancer Control
Plans [45] should also be considered.
5.6. A pan-European vision on innovation (a vision and a
will)
 Finally, European cancer agencies may help build political
will across different countries to embrace innovations. They
may contribution to Europe-wide researchdin true
collaboration between the various Directorates of the Eu-
ropean Commissiondlooking at how different healthcare
systems may foster and evaluate innovations using common
approaches and measures.
 These recommendations should be embedded in revised
National Cancer Control Plans, which should be reviewed
on a regular basis to take account of the continuously
evolving care and treatment landscape.
6. Conclusions
Innovation requires investment, and this investment is
needed if we are to continuously improve the lives andhopes of cancer patients across Europe despite the
financial pressures on our healthcare systems. Adopting
a culture of innovation requires a multidisciplinary team
approach, with the patient at the centre and an integral
part of the team. It must take a whole-system and
whole-patient perspective on cancer care, address unmet
patient needs and be guided by high-quality real-world
data, including patient-relevant outcomes and actual
costs of care; these factors reflect the impact of any
innovation in clinical practice. Similarly, patient orga-
nisations need to be actively engaged with other key
stakeholders in the planning and evaluation of all as-
pects of cancer care.
This article is intended as a starting point to engage
all relevant professionals involved in cancer care, as well
as the patient and care community, in finding sustain-
able solutions to foster innovation within current and
future cancer care. ECCO is committed to working with
its member societies, patient organisations and the
cancer community at large, to help identify sustainable
ways to identify and integrate the most meaningful in-
novations into all aspects of cancer care. It is also
committed to working with, and building on, profes-
sional educational efforts already being made by the
European School of Oncology, ESTRO, European So-
ciety of Surgical Oncology and others to build multi-
disciplinary excellence in cancer care. It is our hope that
this article may contribute to those efforts and be
developed into a concrete action plan that ECCO and its
member societies may follow to help contribute to sus-
tainable, innovative cancer care for patients in years to
come.
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